var data={"title":"Ciclesonide (oral inhalation): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ciclesonide (oral inhalation): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/387890?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ciclesonide-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ciclesonide (oral inhalation): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=ciclesonide-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ciclesonide (oral inhalation): Pediatric drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520685\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alvesco</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002711\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Alvesco</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8007866\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Inhalant (Oral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002780\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Asthma:</b> Inhalation: <b>Note:</b> Titrate to the lowest effective dose once asthma stability is achieved:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling (metered dose inhaler [MDI]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prior therapy with bronchodilators alone: Initial: 80 mcg twice daily (maximum dose: 160 mcg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prior therapy with inhaled corticosteroids: Initial: 80 mcg twice daily (maximum dose: 320 mcg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prior therapy with oral corticosteroids: Initial: 320 mcg twice daily (maximum dose: 320 mcg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling (MDI):</i> Initial: 400 mcg once daily; more severe asthma may require 400 mcg twice daily; maintenance: 100 to 800 mcg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Asthma guidelines:</i> Global Initiative for Asthma guidelines (GINA 2016): HFA inhaler (administer in divided doses twice daily):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&quot;Low&quot; dose: 80 to 160 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&quot;Medium&quot; dose: &gt;160 to 320 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&quot;High&quot; dose: &gt;320 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Conversion: </b>\n      <i>Conversion from oral to orally inhaled steroid:</i> Initiation of oral inhalation therapy should begin in patients who have previously been stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin at least 1 week after starting inhaled therapy. Manufacturer's labeling recommends reducing prednisone dose no more rapidly than &le;2.5 mg/day on a weekly basis. In the presence of withdrawal symptoms, resume previous OCS dose for 1 week before attempting further dose reductions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002779\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ciclesonide-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ciclesonide (oral inhalation): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Asthma:</b> Inhalation: <b>Note:</b> Titrate to the lowest effective dose once asthma stability is achieved:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling (MDI):</i> Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling (MDI):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 6 to 11 years: Initial: 100 to 200 mcg once daily; maintenance: 100 to 200 mcg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Asthma guidelines:</i> Global Initiative for Asthma guidelines (GINA 2017): HFA inhaler (refers to available US products):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &le;5 years: &quot;Low&quot; dose: 160 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 6 to 11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&quot;Low&quot; dose: 80 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&quot;Medium&quot; dose: &gt;80 to 160 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&quot;High&quot; dose: &gt;160 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002781\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14080402\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer labeling (has not been studied); however, dose adjustments may not be necessary as  &le;20% of drug is eliminated renally.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14080403\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520686\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alvesco: 80 mcg/actuation (6.1 g); 160 mcg/actuation (6.1 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002712\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21005912\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Alvesco 6.1 g canisters contain 60 inhalations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002813\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol for oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alvesco: 100 mcg/inhalation [30-, 60-, and 120 metered actuations]; 200 mcg/inhalation [30-, 60-, and 120 metered actuations]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002790\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metered dose inhaler: Prime the inhaler by actuating 3 times before the first use or when the inhaler has not been used for more than 10 consecutive days; no need to shake inhaler before use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Remove mouthpiece cover, place inhaler in mouth, close lips around mouthpiece, and inhale slowly and deeply. Press down on top of inhaler after slow inhalation has begun. Remove inhaler while holding breath for approximately 10 seconds. Breathe out slowly and replace mouthpiece on inhaler. Rinse mouth with water (and spit out) after inhalation. Do not wash or place inhaler in water. Clean mouthpiece using a dry cloth or tissue once weekly. Discard after the &quot;discard by&quot; date or after labeled number of doses has been used, even if container is not completely empty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002713\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> Maintenance treatment of asthma as prophylactic therapy in patients &ge;12 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not indicated for relief of acute bronchospasm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guideline recommendations: A low-dose inhaled corticosteroid <i>(in addition to an as-needed, short-acting beta<sub>2</sub>-agonist) </i>is the initial preferred long-term control medication for children, adolescents, and adult patients with persistent asthma who are candidates for treatment according to a stepwise treatment approach (GINA 2017; NAEPP 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002728\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Facial edema (&ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&ge;3%), fatigue (&ge;3%), voice disorder (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Urticaria (&ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastroenteritis (&ge;3%), oral candidiasis (&ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (&ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&ge;3%), back pain (&ge;3%), limb pain (&ge;3%), musculoskeletal chest pain (&ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (&ge;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (&le;9%), nasal congestion (&le;6%), pharyngolaryngeal pain (&le;5%), hoarseness (&ge;3%), pneumonia (&ge;3%), sinusitis (&ge;3%), paradoxical bronchospasm (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema (with swelling of lip/pharynx/tongue), cataract, chest discomfort, increased gamma-glutamyl transferase, increased intraocular pressure, increased serum ALT, nausea, palpitations, pharyngeal candidiasis, skin rash, weight gain, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002718\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ciclesonide or any component of the formulation; primary treatment of acute asthma or status asthmaticus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Untreated fungal, bacterial, or tuberculosis infections of the respiratory tract; moderate to severe bronchiectasis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002719\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Select surgical patients on long-term, high-dose, inhaled corticosteroid (ICS), should be given stress doses of hydrocortisone intravenously during the surgical period and the dose reduced rapidly within 24 hours after surgery (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: May occur with wheezing after inhalation; if this occurs, stop steroid and treat with a fast-acting bronchodilator.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox and measles should be avoided; use caution in patients with active or quiescent TB infections or in patients with ocular herpes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrush: <i>Candida albicans</i> infections (mostly mild to moderate) of the mouth and pharynx may occur with orally inhaled corticosteroid use; interruption of therapy may be necessary at times while antifungal therapy is employed; advise patients to rinse mouth after use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasculitis: Rare cases of vasculitis (eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]) or other eosinophilic conditions (eg, vasculitic rash, decreased pulmonary function, cardiac complications) can occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Not to be used in status asthmaticus or for the relief of acute bronchospasm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone mineral density: Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants or oral corticosteroids); long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution following acute MI; corticosteroids have been associated with myocardial rupture. Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Systemic exposure to the active metabolite is increased in moderate to severe impairment; however, dosage adjustments are not recommended in hepatic impairment; monitor for increased systemic effects, particularly in patients with severe hepatic impairment, including cirrhosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred with corticosteroids especially during initial treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use in renally impaired patients has not been studied; however, &le;20% of drug is eliminated renally.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in elderly patients in the smallest possible effective dose for the shortest duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 cm per year [range: 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002758\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002759\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9045&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002714\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002715\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Hypoadrenalism may occur in infants born to mothers receiving corticosteroids during pregnancy. Based on available data, an overall increased risk of congenital malformations or a decrease in fetal growth has not been associated with maternal use of inhaled corticosteroids during pregnancy (Bakhireva 2005; NAEPP 2005; Namazy 2004). Uncontrolled asthma is associated with adverse events in pregnancy (increased risk of perinatal mortality, pre-eclampsia, preterm birth, low birth weight infants). Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy (most information available using budesonide) (ACOG 2008; NAEPP 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13766078\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of ciclesonide are absorbed following oral inhalation to produce detectable amounts in breast milk; however, oral absorption is limited (&lt;1%). The manufacturer recommends that caution be exercised when administering ciclesonide to nursing women. The use of inhaled corticosteroids is not considered a contraindication to breastfeeding (NAEPP 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002793\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Growth (adolescents and children via stadiometry) signs/symptoms of HPA axis suppression/adrenal insufficiency; ocular effects (eg, cataracts, increased intraocular pressure, glaucoma); bone mineral density; signs/symptoms of oral candidiasis; FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002765\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ciclesonide is a nonhalogenated, glucocorticoid prodrug that is hydrolyzed to the pharmacologically active metabolite des-ciclesonide following administration. Des-ciclesonide has a high affinity for the glucocorticoid receptor and exhibits anti-inflammatory activity. The mechanism of action for corticosteroids is believed to be a combination of three important properties &minus; anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002767\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: &gt;4 weeks for maximum benefit </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: 52% (lung deposition)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Ciclesonide: 2.9 L/kg; des-ciclesonide: 12.1 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &ge;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Ciclesonide hydrolyzed to its active metabolite, des-ciclesonide via esterases in nasal mucosa and lungs; des-ciclesonide undergoes further hepatic metabolism primarily via  CYP3A4 and to a lesser extent via CYP2D6 </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 63% (active metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Ciclesonide: 0.7 hours; des-ciclesonide: 6-7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: ~1 hour (des-ciclesonide)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (66%); urine (&le;20% as active metabolite) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002815\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Alvesco Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mcg/ACT (6.1 g): $301.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mcg/ACT (6.1 g): $301.88</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390225\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alvesco (AE, AR, AT, AU, BB, BE, BR, CH, CO, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, JP, KR, LB, LT, LV, MT, MY, NI, NL, NO, NZ, PA, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TR, TW, VE);</li>\n      <li>Cesonide (BD);</li>\n      <li>Cicletex (AR);</li>\n      <li>Ciclocip (LK);</li>\n      <li>Ciclohale (LB);</li>\n      <li>Ciclotis (LK);</li>\n      <li>Disbronc (CL);</li>\n      <li>Ezonide (BD);</li>\n      <li>Osonide (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 90, February 2008: Asthma in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2008, 111(2 Pt 1):457-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-oral-inhalation-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alvesco (ciclesonide) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alvesco (ciclesonide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakhireva LN, Jones KL, Schatz M, et al, &ldquo;Asthma Medication Use in Pregnancy and Fetal Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2005, 116(3):503-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-oral-inhalation-drug-information/abstract-text/16159616/pubmed\" target=\"_blank\" id=\"16159616\">16159616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bateman E, Karpel J, Casale T, et al, &ldquo;Ciclesonide Reduces the Need for Oral Steroid Use in Adult Patients With Severe, Persistent Asthma,&rdquo; <i>Chest</i>, 2006, 129(5):1176-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-oral-inhalation-drug-information/abstract-text/16685007/pubmed\" target=\"_blank\" id=\"16685007\">16685007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chmielewska M, Akst LM. Dysphonia associated with the use of inhaled corticosteroids. <i>Curr Opin Otolaryngol Head Neck Surg.</i> 2015; 23(3):255-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-oral-inhalation-drug-information/abstract-text/25887975/pubmed\" target=\"_blank\" id=\"25887975\">25887975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Derendorf H, &ldquo;Pharmacokinetic and Pharmacodynamic Properties of Inhaled Ciclesonide,&rdquo; <i>J Clin Pharmacol</i>, 2007, 47(6):782-9<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-oral-inhalation-drug-information/abstract-text/17412829/pubmed\" target=\"_blank\" id=\"17412829\">17412829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org. Updated 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo; <i>J Natl Cancer Inst</i>, 2002, 94(22):1712-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-oral-inhalation-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M, Long L, et al, &ldquo;Use of Inhaled Steroids by Pregnant Asthmatic Women Does Not Reduce Intrauterine Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2004, 113(3):427-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-oral-inhalation-drug-information/abstract-text/15007341/pubmed\" target=\"_blank\" id=\"15007341\">15007341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 3, &quot;Guidelines for the Diagnosis and Management of Asthma,&quot; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearlman DS, Berger WE, Kerwin E, et al, &ldquo;Once-Daily Ciclesonide Improves Lung Function and is Well Tolerated by Patients With Mild-to-Moderate Persistent Asthma,&rdquo; <i>J Allergy Clin Immunol</i>, 2005, 116(6):1206-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-oral-inhalation-drug-information/abstract-text/16337447/pubmed\" target=\"_blank\" id=\"16337447\">16337447</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pedersen S, Engelst&auml;tter R, Weber HJ, et al, &ldquo;Efficacy and Safety of Ciclesonide Once Daily and Fluticasone Propionate Twice Daily in Children With Asthma,&rdquo; <i>Pulm Pharmacol Ther</i>, 2009, 22(3):214-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-oral-inhalation-drug-information/abstract-text/19141327/pubmed\" target=\"_blank\" id=\"19141327\">19141327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pedersen S, Garcia Garcia ML, Manjra A, et al, &ldquo;A Comparative Study of Inhaled Ciclesonide 160 mcg/day and Fluticasone Propionate 176 mcg/day in Children With Asthma,&rdquo; <i>Pediatr Pulmonol</i>, 2006, 41(10):954-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-oral-inhalation-drug-information/abstract-text/16868976/pubmed\" target=\"_blank\" id=\"16868976\">16868976</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9045 Version 133.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520685\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8002711\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8007866\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8002780\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8002779\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8002781\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14080402\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14080403\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24520686\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8002712\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21005912\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F8002813\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8002790\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8002713\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8002728\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8002718\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8002719\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8002758\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8002759\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8002714\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8002715\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13766078\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8002793\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8002765\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8002767\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8002815\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390225\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9045|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ciclesonide-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Ciclesonide (oral inhalation): Patient drug information \t</a></li><li><a href=\"topic.htm?path=ciclesonide-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">Ciclesonide (oral inhalation): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}